2019 Q2 Form 10-Q Financial Statement
#000162828019010579 Filed on August 09, 2019
Income Statement
| Concept | 2019 Q2 | 2018 Q4 | 2018 Q2 |
|---|---|---|---|
| Revenue | $130.1M | $105.5M | $123.0M |
| YoY Change | 5.73% | -59.34% | 51.28% |
| Cost Of Revenue | $101.4M | $79.40M | $99.71M |
| YoY Change | 1.66% | -55.99% | 49.55% |
| Gross Profit | $28.69M | $26.00M | $23.30M |
| YoY Change | 23.13% | -67.13% | 59.15% |
| Gross Profit Margin | 22.06% | 24.64% | 18.94% |
| Selling, General & Admin | $9.500M | $15.80M | $10.90M |
| YoY Change | -12.84% | 54.9% | 122.45% |
| % of Gross Profit | 33.12% | 60.77% | 46.78% |
| Research & Development | |||
| YoY Change | |||
| % of Gross Profit | |||
| Depreciation & Amortization | $4.455M | $4.480M | $4.918M |
| YoY Change | -9.42% | -76.13% | 2.33% |
| % of Gross Profit | 15.53% | 17.23% | 21.11% |
| Operating Expenses | $115.3M | $20.30M | $115.5M |
| YoY Change | -0.17% | -33.66% | 49.53% |
| Operating Profit | $14.73M | $5.700M | $7.150M |
| YoY Change | 105.99% | -88.25% | 76.26% |
| Interest Expense | $311.0K | -$5.400M | $110.7K |
| YoY Change | 180.98% | -138.85% | 19149.22% |
| % of Operating Profit | 2.11% | -94.74% | 1.55% |
| Other Income/Expense, Net | $145.0K | $500.0K | $2.240M |
| YoY Change | -93.53% | 400.0% | -214.62% |
| Pretax Income | $14.87M | -$2.900M | $9.389M |
| YoY Change | 58.4% | -104.63% | 346.63% |
| Income Tax | $4.209M | -$1.000M | $1.524M |
| % Of Pretax Income | 28.3% | 16.23% | |
| Net Earnings | $3.545M | -$3.100M | $2.664M |
| YoY Change | 33.07% | -108.18% | 33.56% |
| Net Earnings / Revenue | 2.73% | -2.94% | 2.17% |
| Basic Earnings Per Share | $0.10 | $0.08 | |
| Diluted Earnings Per Share | $0.09 | -$92.26K | $0.07 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 34.54M shares | 34.08M shares | 32.67M shares |
| Diluted Shares Outstanding | 37.96M shares | 37.85M shares |
Balance Sheet
| Concept | 2019 Q2 | 2018 Q4 | 2018 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $53.90M | $108.0M | $102.3M |
| YoY Change | -47.31% | 7.04% | 227.88% |
| Cash & Equivalents | $52.73M | $106.9M | $101.1M |
| Short-Term Investments | $1.100M | $1.100M | $1.100M |
| Other Short-Term Assets | $13.60M | $8.400M | $14.60M |
| YoY Change | -6.85% | -60.19% | 4766.67% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $16.71M | $7.735M | $34.54M |
| Other Receivables | $12.90M | $1.003M | $1.300M |
| Total Short-Term Assets | $167.6M | $172.9M | $152.8M |
| YoY Change | 9.73% | 19.91% | 305.21% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $12.10M | $12.72M | $13.30M |
| YoY Change | -8.99% | -7.91% | 1038.77% |
| Goodwill | $209.3M | $185.8M | $189.6M |
| YoY Change | 10.39% | 115.56% | 11586.09% |
| Intangibles | $109.1M | $86.88M | $94.93M |
| YoY Change | 14.9% | -16.09% | 5108.5% |
| Long-Term Investments | $35.90M | $34.88M | $23.55M |
| YoY Change | 52.48% | 59.23% | |
| Other Assets | $1.352M | $1.206M | $1.516M |
| YoY Change | -10.83% | -26.12% | 582.8% |
| Total Long-Term Assets | $400.7M | $340.1M | $358.2M |
| YoY Change | 11.86% | -1.83% | 6298.06% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $167.6M | $172.9M | $152.8M |
| Total Long-Term Assets | $400.7M | $340.1M | $358.2M |
| Total Assets | $568.3M | $513.0M | $511.0M |
| YoY Change | 11.22% | 4.56% | 1080.12% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $4.769M | $4.482M | $3.633M |
| YoY Change | 31.27% | 18.36% | -77.58% |
| Accrued Expenses | $5.900M | $5.000M | $7.900M |
| YoY Change | -25.32% | -76.74% | |
| Deferred Revenue | $15.47M | $9.024M | |
| YoY Change | 3509.69% | ||
| Short-Term Debt | $0.00 | $0.00 | $300.0K |
| YoY Change | -100.0% | -100.0% | -93.88% |
| Long-Term Debt Due | $100.0K | $0.00 | $100.0K |
| YoY Change | 0.0% | -100.0% | |
| Total Short-Term Liabilities | $78.34M | $72.02M | $89.12M |
| YoY Change | -12.1% | -34.29% | 118.22% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $45.10M | $0.00 | $13.60M |
| YoY Change | 231.62% | -100.0% | 172.0% |
| Other Long-Term Liabilities | $12.60M | $1.200M | $9.800M |
| YoY Change | 28.57% | -93.75% | 1300.0% |
| Total Long-Term Liabilities | $84.32M | $34.32M | $51.13M |
| YoY Change | 64.91% | -23.26% | 797.01% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $78.34M | $72.02M | $89.12M |
| Total Long-Term Liabilities | $84.32M | $34.32M | $51.13M |
| Total Liabilities | $162.7M | $106.3M | $140.2M |
| YoY Change | 15.98% | -31.09% | 200.72% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | $21.47M | $17.79M | $7.562M |
| YoY Change | 183.98% | 925.53% | -118.32% |
| Common Stock | $34.64K | $34.58K | $32.84K |
| YoY Change | 5.47% | 7.04% | 444.36% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $185.4M | $180.5M | $169.6M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $568.3M | $513.0M | $511.0M |
| YoY Change | 11.22% | 4.56% | 1080.09% |
Cashflow Statement
| Concept | 2019 Q2 | 2018 Q4 | 2018 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | $3.545M | -$3.100M | $2.664M |
| YoY Change | 33.07% | -108.18% | 33.56% |
| Depreciation, Depletion And Amortization | $4.455M | $4.480M | $4.918M |
| YoY Change | -9.42% | -76.13% | 2.33% |
| Cash From Operating Activities | -$18.05M | -$6.360M | $8.680M |
| YoY Change | -307.95% | -120.93% | -61.63% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$280.0K | -$300.0K | -$190.0K |
| YoY Change | 47.37% | -85.15% | 375.0% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$49.86M | -$4.630M | -$19.58M |
| YoY Change | 154.65% | -146.02% | |
| Cash From Investing Activities | -$50.14M | -$4.930M | -$19.78M |
| YoY Change | 153.49% | -161.39% | 49350.0% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 31.44M | -5.810M | -1.490M |
| YoY Change | -2210.07% | -61.34% | 3625.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -18.05M | -6.360M | 8.680M |
| Cash From Investing Activities | -50.14M | -4.930M | -19.78M |
| Cash From Financing Activities | 31.44M | -5.810M | -1.490M |
| Net Change In Cash | -36.75M | -17.10M | -12.59M |
| YoY Change | 191.9% | -173.14% | -155.86% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$18.05M | -$6.360M | $8.680M |
| Capital Expenditures | -$280.0K | -$300.0K | -$190.0K |
| Free Cash Flow | -$17.77M | -$6.060M | $8.870M |
| YoY Change | -300.34% | -118.7% | -60.86% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018 | ameh |
Adjustments For Medical Liabilities
AdjustmentsForMedicalLiabilities
|
-781924 | USD |
| ameh |
Adjustments For Medical Liabilities
AdjustmentsForMedicalLiabilities
|
-155907 | USD | |
| CY2018Q2 | ameh |
Adjustments To Additional Paid In Capital Merger Purchase Price Adjustment
AdjustmentsToAdditionalPaidInCapitalMergerPurchasePriceAdjustment
|
868000 | USD |
| CY2018Q4 | ameh |
All Inclusive Population Based Payments To Be Received
AllInclusivePopulationBasedPaymentsToBeReceived
|
5500000 | USD |
| CY2018 | ameh |
Antidilutive Securities Excluded From Earnings Computation Shares
AntidilutiveSecuritiesExcludedFromEarningsComputationShares
|
1682110 | shares |
| ameh |
Antidilutive Securities Excluded From Earnings Computation Shares
AntidilutiveSecuritiesExcludedFromEarningsComputationShares
|
1775561 | shares | |
| CY2016Q4 | ameh |
Business Combination Shares Held Back To Secure Indemnification Percentage
BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
|
0.1 | |
| CY2018Q2 | ameh |
Business Combination Shares Held Back To Secure Indemnification Percentage
BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
|
0.1 | |
| ameh |
Business Combination Shares Held Back To Secure Indemnification Percentage
BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
|
0.1 | ||
| CY2019Q2 | ameh |
Business Combination Shares Held Back To Secure Indemnification Percentage
BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
|
0.1 | |
| ameh |
Business Combination Shares Held Back To Secure Indemnification Percentage
BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
|
0.1 | ||
| CY2016Q4 | ameh |
Business Combination Shares Held Back To Secure Indemnification Period
BusinessCombinationSharesHeldBackToSecureIndemnificationPeriod
|
P24M | |
| CY2016Q4 | ameh |
Business Combination Shares Held Back To Secure Indemnification Shares Issued On First Anniversary Percentage
BusinessCombinationSharesHeldBackToSecureIndemnificationSharesIssuedOnFirstAnniversaryPercentage
|
0.5 | |
| CY2016Q4 | ameh |
Business Combination Shares Held Back To Secure Indemnification Shares Issued On Second Anniversary Percentage
BusinessCombinationSharesHeldBackToSecureIndemnificationSharesIssuedOnSecondAnniversaryPercentage
|
0.5 | |
| ameh |
Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
|
47 | USD | |
| ameh |
Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
|
0 | USD | |
| ameh |
Class Of Warrant Or Right Cancelled In Period
ClassOfWarrantOrRightCancelledInPeriod
|
0 | shares | |
| CY2019Q2 | ameh |
Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
|
3290371 | shares |
| ameh |
Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
|
3290371 | shares | |
| ameh |
Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
|
P2Y5M23D | ||
| CY2018 | ameh |
Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
|
P2Y11M19D | |
| ameh |
Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
|
P2Y5M23D | ||
| CY2019Q2 | ameh |
Class Of Warrants Or Right Exercises In Period Aggregate Intrinsic Value
ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue
|
300000 | USD |
| CY2019Q2 | ameh |
Class Of Warrants Or Right Forfeitures In Period Aggregate Intrinsic Value
ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue
|
0 | USD |
| CY2019Q2 | ameh |
Class Of Warrants Or Right Grant In Period Aggregate Intrinsic Value
ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue
|
0 | USD |
| CY2018Q4 | ameh |
Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
|
33100000 | USD |
| CY2019Q2 | ameh |
Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
|
22300000 | USD |
| CY2018Q4 | ameh |
Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
|
9.93 | |
| CY2019Q2 | ameh |
Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
|
9.93 | |
| ameh |
Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Exercised In Period
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod
|
9.41 | ||
| ameh |
Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Forfeited In Period
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod
|
0.00 | ||
| ameh |
Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Grant In Period
ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod
|
0.00 | ||
| ameh |
Deferred Tax Liability Adjusted To Goodwill
DeferredTaxLiabilityAdjustedToGoodwill
|
1110456 | USD | |
| ameh |
Deferred Tax Liability Adjusted To Goodwill
DeferredTaxLiabilityAdjustedToGoodwill
|
8355343 | USD | |
| CY2018Q4 | ameh |
Fiduciary Accounts Payable Current
FiduciaryAccountsPayableCurrent
|
1538598 | USD |
| CY2019Q2 | ameh |
Fiduciary Accounts Payable Current
FiduciaryAccountsPayableCurrent
|
1798807 | USD |
| ameh |
Increase Decrease In Dividends Payable
IncreaseDecreaseInDividendsPayable
|
617210 | USD | |
| ameh |
Increase Decrease In Dividends Payable
IncreaseDecreaseInDividendsPayable
|
0 | USD | |
| ameh |
Increase Decrease In Incentives Payable
IncreaseDecreaseInIncentivesPayable
|
-16395926 | USD | |
| ameh |
Increase Decrease In Incentives Payable
IncreaseDecreaseInIncentivesPayable
|
0 | USD | |
| ameh |
Increase Decrease In Medical Liabilities
IncreaseDecreaseInMedicalLiabilities
|
2881017 | USD | |
| ameh |
Increase Decrease In Medical Liabilities
IncreaseDecreaseInMedicalLiabilities
|
-3818517 | USD | |
| ameh |
Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
|
0 | USD | |
| ameh |
Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
|
1098111 | USD | |
| ameh |
Increase Decrease In Other Operating Lease Liabilities
IncreaseDecreaseInOtherOperatingLeaseLiabilities
|
0 | USD | |
| ameh |
Increase Decrease In Other Operating Lease Liabilities
IncreaseDecreaseInOtherOperatingLeaseLiabilities
|
-1043927 | USD | |
| ameh |
Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
|
2772749 | USD | |
| ameh |
Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
|
2740403 | USD | |
| CY1999Q3 | ameh |
Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement
InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement
|
P30Y | |
| CY2018Q4 | ameh |
Investment In Privately Held Entity That Does Not Report Net Asset Value
InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
|
405000 | USD |
| CY2019Q2 | ameh |
Investment In Privately Held Entity That Does Not Report Net Asset Value
InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
|
405000 | USD |
| CY2018Q4 | ameh |
Liability For Unissued Equity Shares Noncurrent
LiabilityForUnissuedEquitySharesNoncurrent
|
1185025 | USD |
| CY2019Q2 | ameh |
Liability For Unissued Equity Shares Noncurrent
LiabilityForUnissuedEquitySharesNoncurrent
|
1185025 | USD |
| CY2018 | ameh |
Medical Liabilities Acquired
MedicalLiabilitiesAcquired
|
0 | USD |
| ameh |
Medical Liabilities Acquired
MedicalLiabilitiesAcquired
|
13119714 | USD | |
| CY2017Q4 | ameh |
Medical Liabilities Current
MedicalLiabilitiesCurrent
|
63972318 | USD |
| CY2018Q4 | ameh |
Medical Liabilities Current
MedicalLiabilitiesCurrent
|
33641701 | USD |
| CY2019Q2 | ameh |
Medical Liabilities Current
MedicalLiabilitiesCurrent
|
42942898 | USD |
| CY2018Q1 | ameh |
Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity
NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
|
2746903 | USD |
| CY2018Q2 | ameh |
Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity
NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
|
3007968 | USD |
| CY2019Q1 | ameh |
Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity
NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
|
549892 | USD |
| CY2019Q2 | ameh |
Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity
NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
|
3768191 | USD |
| CY2018Q2 | ameh |
Noncontrolling Interest Increase From Capital Charge
NoncontrollingInterestIncreaseFromCapitalCharge
|
27500 | USD |
| ameh |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
41624 | shares | |
| ameh |
Number Of Warrants Granted
NumberOfWarrantsGranted
|
0 | shares | |
| ameh |
Payment Of Investment Privately Held Entity Does Not Report To Nav Per Share
PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare
|
405000 | USD | |
| ameh |
Payment Of Investment Privately Held Entity Does Not Report To Nav Per Share
PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare
|
0 | USD | |
| CY2018Q4 | ameh |
Payment Of Revenue
PaymentOfRevenue
|
5500000 | USD |
| ameh |
Payment Of Revenue
PaymentOfRevenue
|
7300000 | USD | |
| ameh |
Payment Of Revenue
PaymentOfRevenue
|
8300000 | USD | |
| CY2018 | ameh |
Payments To Cms Based For Medical Liabilities
PaymentsToCMSBasedForMedicalLiabilities
|
34464826 | USD |
| ameh |
Payments To Cms Based For Medical Liabilities
PaymentsToCMSBasedForMedicalLiabilities
|
0 | USD | |
| ameh |
Percentage Of Financial Guarantee Benchmark Amount
PercentageOfFinancialGuaranteeBenchmarkAmount
|
0.02 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
675515 | USD | |
| CY2018Q4 | ameh |
Subcontractor Ipa Risk Pool Payable
SubcontractorIpaRiskPoolPayable
|
2532750 | USD |
| CY2019Q2 | ameh |
Subcontractor Ipa Risk Pool Payable
SubcontractorIpaRiskPoolPayable
|
2760162 | USD |
| CY2018Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
4300000 | USD |
| CY2019Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
2900000 | USD |
| CY2019Q1 | ameh |
Stock Issued During The Period Value Of Exercise Of Option And Warrants
StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
|
139974 | USD |
| CY2019Q2 | ameh |
Stock Issued During The Period Value Of Exercise Of Option And Warrants
StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
|
758128 | USD |
| CY2018Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
|
0 | USD |
| us-gaap |
Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
|
0 | USD | |
| ameh |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period Of Payment Upon Finalization Of Settlement Report
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
|
P30D | ||
| ameh |
Share Based Compensation Arrangement By Share Based Payment Award Cashless Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod
|
60536 | shares | |
| ameh |
Share Based Compensation Arrangement By Share Based Payment Award Cashless Options Exercises In Period Net
ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriodNet
|
47576 | shares | |
| ameh |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
|
0 | ||
| ameh |
Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
|
210625 | shares | |
| ameh |
Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
|
41624 | shares | |
| CY2018Q4 | ameh |
Specialty Capitation Payable Current
SpecialtyCapitationPayableCurrent
|
300000 | USD |
| CY2019Q2 | ameh |
Specialty Capitation Payable Current
SpecialtyCapitationPayableCurrent
|
300000 | USD |
| ameh |
Stock Issued During Period Shares Merger
StockIssuedDuringPeriodSharesMerger
|
480212 | shares | |
| CY2018Q1 | ameh |
Stock Issued During The Period Value Of Exercise Of Option And Warrants
StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
|
1923784 | USD |
| CY2018Q2 | ameh |
Stock Issued During The Period Value Of Exercise Of Option And Warrants
StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
|
423545 | USD |
| ameh |
Warrant Issued During Period Value Stock Options Exercised
WarrantIssuedDuringPeriodValueStockOptionsExercised
|
1500000 | USD | |
| ameh |
Warrant Issued During Period Value Stock Options Exercised
WarrantIssuedDuringPeriodValueStockOptionsExercised
|
400000 | USD | |
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2019 | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2019-06-30 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001083446 | ||
| CY2019Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
35899684 | shares |
| dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
| dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
Apollo Medical Holdings, Inc. | ||
| dei |
Entity Shell Company
EntityShellCompany
|
false | ||
| dei |
Entity Small Business
EntitySmallBusiness
|
false | ||
| CY2018Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
25075489 | USD |
| CY2019Q2 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
30658273 | USD |
| CY2018Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4481544 | USD |
| CY2019Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4768708 | USD |
| CY2018Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
7127217 | USD |
| CY2019Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
16707314 | USD |
| CY2018Q4 | us-gaap |
Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
|
49328739 | USD |
| CY2019Q2 | us-gaap |
Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
|
64057647 | USD |
| CY2018Q4 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
11621861 | USD |
| CY2019Q2 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
0 | USD |
| CY2018Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
2251741 | USD |
| CY2019Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
3249220 | USD |
| CY2018Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
162723051 | USD |
| CY2019Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
163891843 | USD |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1036326 | USD | |
| CY2019Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
|
2314429 | USD |
| us-gaap |
Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
|
1363415 | USD | |
| CY2018Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
4200000 | USD |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
8600000 | USD | |
| CY2019Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
3800000 | USD |
| CY2018Q4 | us-gaap |
Assets Current
AssetsCurrent
|
172862792 | USD |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
7700000 | USD | |
| CY2018Q4 | us-gaap |
Assets
Assets
|
512999049 | USD |
| CY2019Q2 | us-gaap |
Assets
Assets
|
568329965 | USD |
| CY2019Q2 | us-gaap |
Assets Current
AssetsCurrent
|
167625710 | USD |
| CY2018Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
86627847 | USD |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
85500745 | USD |
| CY2019Q2 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
28534501 | USD |
| CY2019Q2 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
29684329 | USD |
| CY2018Q4 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
340136257 | USD |
| CY2019Q2 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
400704255 | USD |
| CY2018Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
1066103 | USD |
| CY2019Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
1074280 | USD |
| CY2018Q4 | us-gaap |
Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
|
674000 | USD |
| CY2018Q4 | us-gaap |
Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
|
119000 | USD |
| CY2018Q4 | us-gaap |
Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
|
119000 | USD |
| CY2018Q4 | us-gaap |
Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
|
119000 | USD |
| CY2018Q4 | us-gaap |
Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
|
119000 | USD |
| CY2018Q4 | us-gaap |
Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
|
119000 | USD |
| CY2018Q4 | us-gaap |
Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
|
79000 | USD |
| CY2018Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
101132237 | USD |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
106891503 | USD |
| CY2019Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
52726305 | USD |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
118500095 | USD |
| CY2018Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
109918459 | USD |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
107636973 | USD |
| CY2019Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
57003987 | USD |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-8581636 | USD | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-50632986 | USD | |
| CY2019Q2 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
80700000 | USD |
| CY2018Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
3331995 | shares |
| CY2019Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
3290371 | shares |
| CY2018Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2019Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2018Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2019Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2018Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
34578040 | shares |
| CY2019Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
34638812 | shares |
| CY2018Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
34578 | USD |
| CY2019Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
34639 | USD |
| CY2018Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
9024235 | USD |
| CY2019Q2 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
15471349 | USD |
| us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
500000 | USD | |
| CY2018Q2 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
99705571 | USD |
| us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
184320257 | USD | |
| CY2019Q2 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
101363101 | USD |
| us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
184795575 | USD | |
| CY2018Q1 | us-gaap |
Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
|
1002468 | USD |
| CY2018Q4 | us-gaap |
Deferred Credits And Other Liabilities Current
DeferredCreditsAndOtherLiabilitiesCurrent
|
9100000 | USD |
| CY2019Q2 | us-gaap |
Deferred Credits And Other Liabilities Current
DeferredCreditsAndOtherLiabilitiesCurrent
|
15500000 | USD |
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
706813 | USD | |
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-549198 | USD | |
| CY2018Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
19615935 | USD |
| CY2019Q2 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
26651678 | USD |
| CY2018Q2 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
4918078 | USD |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
9976590 | USD | |
| CY2019Q2 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
4454571 | USD |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
8872152 | USD | |
| CY2018Q4 | us-gaap |
Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
|
17500000 | USD |
| CY2019Q2 | us-gaap |
Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
|
17500000 | USD |
| CY2018Q4 | us-gaap |
Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
|
13000000 | USD |
| CY2019Q2 | us-gaap |
Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
|
44600000 | USD |
| CY2018Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.08 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.15 | ||
| CY2019Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.10 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.11 | ||
| CY2018Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.07 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.13 | ||
| CY2019Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.09 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.10 | ||
| CY2018Q4 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
34876980 | USD |
| CY2019Q2 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
35903041 | USD |
| CY2018Q4 | us-gaap |
Equity Securities Fv Ni
EquitySecuritiesFvNi
|
60999 | USD |
| CY2019Q2 | us-gaap |
Equity Securities Fv Ni
EquitySecuritiesFvNi
|
75548 | USD |
| CY2019Q2 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
4391 | USD |
| us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
8970 | USD | |
| CY2019Q2 | us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
4391 | USD |
| us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
8970 | USD | |
| CY2019Q2 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
568512 | USD |
| CY2018Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
101741 | USD |
| CY2019Q2 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
101741 | USD |
| CY2018Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
517261 | USD |
| CY2019Q2 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
466771 | USD |
| CY2019Q2 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
614418 | USD |
| CY2019Q2 | us-gaap |
Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
|
79278 | USD |
| CY2019Q2 | us-gaap |
Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
|
118920 | USD |
| CY2019Q2 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
118920 | USD |
| CY2019Q2 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
118920 | USD |
| CY2019Q2 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
118920 | USD |
| CY2019Q2 | us-gaap |
Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
|
59460 | USD |
| CY2019Q2 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
45906 | USD |
| CY2019Q2 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
25339 | USD |
| us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
50489 | USD | |
| CY2018Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
500000 | USD |
| us-gaap |
Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
|
96521548 | USD | |
| us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
0 | USD | |
| us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
0 | USD | |
| us-gaap |
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
|
0 | USD | |
| us-gaap |
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
|
0 | USD | |
| CY2019Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
11817555 | USD |
| CY2018Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
10893135 | USD |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
22441474 | USD | |
| CY2019Q2 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
500000 | USD |
| CY2018Q4 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
200000 | USD |
| CY2019Q2 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
200000 | USD |
| CY2019Q2 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
25339 | USD |
| us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
50489 | USD | |
| CY2019Q2 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.0300 | |
| CY2019Q2 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P5Y0M | |
| CY2018Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
57600117 | USD |
| CY2019Q2 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
65264142 | USD |
| CY2019Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
48862000 | USD |
| CY2019Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
14968000 | USD |
| CY2019Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
8155000 | USD |
| CY2019Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
10090000 | USD |
| CY2019Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
11744000 | USD |
| CY2019Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
13257000 | USD |
| CY2019Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
107076000 | USD |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-41782 | USD | |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | USD | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
22081515 | USD | |
| CY2018Q4 | us-gaap |
Goodwill
Goodwill
|
185805880 | USD |
| CY2019Q2 | us-gaap |
Goodwill
Goodwill
|
209313824 | USD |
| us-gaap |
Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
|
23507944 | USD | |
| us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | USD | |
| us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | USD | |
| CY2018 | us-gaap |
Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
|
209002961 | USD |
| us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD | |
| us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD | |
| CY2018Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
9389400 | USD |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
32335895 | USD | |
| CY2019Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
14873330 | USD |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
11014960 | USD | |
| CY2018Q2 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
1669861 | USD |
| us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
1641837 | USD | |
| CY2019Q2 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-42282 | USD |
| us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-891939 | USD | |
| CY2018Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1523807 | USD |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
8752647 | USD | |
| CY2019Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
4209399 | USD |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2801158 | USD | |
| us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
11612590 | USD | |
| us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
16700000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-692000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
3340115 | USD | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-4410363 | USD | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-587637 | USD | |
| us-gaap |
Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
|
-298439 | USD | |
| us-gaap |
Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
|
-11621861 | USD | |
| us-gaap |
Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
|
7234874 | USD | |
| us-gaap |
Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
|
12665493 | USD | |
| us-gaap |
Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
|
-722934 | USD | |
| us-gaap |
Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
|
260209 | USD | |
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
95258 | USD | |
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
243112 | USD | |
| us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
0 | USD | |
| us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
11897078 | USD | |
| CY2018Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
144476000 | USD |
| CY2019Q2 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
174334000 | USD |
| CY2018Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
86875883 | USD |
| CY2019Q2 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
109069858 | USD |
| CY2018Q2 | us-gaap |
Interest Expense
InterestExpense
|
110683 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
195684 | USD | |
| CY2019Q2 | us-gaap |
Interest Expense
InterestExpense
|
311049 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
522028 | USD | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
144544 | USD | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
438976 | USD | |
| CY2018Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
492723 | USD |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
762541 | USD | |
| CY2019Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
473664 | USD |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
796672 | USD | |
| CY2019Q2 | us-gaap |
Lease Cost
LeaseCost
|
1164105 | USD |
| us-gaap |
Lease Cost
LeaseCost
|
2196338 | USD | |
| CY2019Q2 | us-gaap |
Lessee Finance Lease Renewal Term1
LesseeFinanceLeaseRenewalTerm1
|
P10Y | |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
18316080 | USD |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
6487401 | USD |
| CY2018Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
1127102 | USD |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
1797423 | USD |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
2077157 | USD |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
2421637 | USD |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
3615177 | USD |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
1917285 | USD |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
4063320 | USD |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P10Y | |
| CY2018Q4 | us-gaap |
Liabilities
Liabilities
|
106337868 | USD |
| CY2019Q2 | us-gaap |
Liabilities
Liabilities
|
162657953 | USD |
| CY2018Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
512999049 | USD |
| CY2019Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
568329965 | USD |
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
72019647 | USD |
| CY2019Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
78337729 | USD |
| CY2018Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
34318221 | USD |
| CY2019Q2 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
84320224 | USD |
| CY2018Q1 | us-gaap |
Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
|
5000000.0 | USD |
| CY2018Q2 | us-gaap |
Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
|
5000000 | USD |
| CY2018 | us-gaap |
Malpractice Loss Contingency Claims Incurred In Period
MalpracticeLossContingencyClaimsIncurredInPeriod
|
36549348 | USD |
| us-gaap |
Malpractice Loss Contingency Claims Incurred In Period
MalpracticeLossContingencyClaimsIncurredInPeriod
|
39744468 | USD | |
| CY2018 | us-gaap |
Malpractice Loss Contingency Claims Incurred In Prior Periods
MalpracticeLossContingencyClaimsIncurredInPriorPeriods
|
167537480 | USD |
| us-gaap |
Malpractice Loss Contingency Claims Incurred In Prior Periods
MalpracticeLossContingencyClaimsIncurredInPriorPeriods
|
60439690 | USD | |
| CY2018Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
1100000 | USD |
| CY2019Q2 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
1100000 | USD |
| CY2019Q2 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
1149828 | USD |
| CY2018Q4 | us-gaap |
Minority Interest
MinorityInterest
|
998320 | USD |
| CY2019Q2 | us-gaap |
Minority Interest
MinorityInterest
|
689935 | USD |
| CY2018Q1 | us-gaap |
Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
|
0 | USD |
| CY2019Q1 | us-gaap |
Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
|
0 | USD |
| CY2019Q2 | us-gaap |
Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
|
941588 | USD |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1731544 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
21630767 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-20265484 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-50245680 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
13415392 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-22018073 | USD | |
| CY2018Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
2664102 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
4824557 | USD | |
| CY2019Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
3545216 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
3684880 | USD | |
| CY2018Q2 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
5201491 | USD |
| us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
18758691 | USD | |
| CY2019Q2 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
7118715 | USD |
| us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
4528922 | USD | |
| CY2018Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
2239653 | USD |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-405950 | USD | |
| CY2018Q4 | us-gaap |
Notes Receivable Related Parties Current
NotesReceivableRelatedPartiesCurrent
|
0 | USD |
| CY2019Q2 | us-gaap |
Notes Receivable Related Parties Current
NotesReceivableRelatedPartiesCurrent
|
6425000 | USD |
| us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
2484439 | USD | |
| CY2019Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
144562 | USD |
| us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | segment | |
| us-gaap |
Number Of Reporting Units
NumberOfReportingUnits
|
3 | unit | |
| CY2018Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
115516784 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
216738321 | USD | |
| CY2019Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
115320798 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
214385827 | USD | |
| CY2018Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
7149747 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
29851456 | USD | |
| CY2019Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
14728768 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
11420910 | USD | |
| CY2019Q2 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1240275 | USD |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
2342959 | USD | |
| CY2019Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
14252760 | USD |
| CY2019Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
14300000 | USD |
| CY2018Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
0 | USD |
| CY2019Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2836010 | USD |
| CY2018Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
0 | USD |
| CY2019Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
11416750 | USD |
| CY2019Q2 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1239312 | USD |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
2272865 | USD | |
| CY2018Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
0 | USD |
| CY2019Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
14319371 | USD |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
14300000 | USD |
| CY2019Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0618 | |
| CY2019Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P6Y10M12D | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
7117000 | USD |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
2848000 | USD |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
489000 | USD |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
487000 | USD |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
783000 | USD |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
2267000 | USD |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
243000 | USD |
| CY2018Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1205962 | USD |
| CY2019Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1351576 | USD |
| CY2018Q4 | us-gaap |
Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
|
1488313 | USD |
| CY2019Q2 | us-gaap |
Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
|
1072563 | USD |
| CY2018Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
187752 | USD |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
275745 | USD | |
| CY2019Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
24229 | USD |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
211345 | USD | |
| CY2018Q4 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
1003133 | USD |
| CY2019Q2 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
12900211 | USD |
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
0 | USD | |
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
40000 | USD | |
| us-gaap |
Payments Of Dividends
PaymentsOfDividends
|
12000000 | USD | |
| us-gaap |
Payments Of Dividends
PaymentsOfDividends
|
10941588 | USD | |
| us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
0 | USD | |
| us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
41518084 | USD | |
| us-gaap |
Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
|
16673840 | USD | |
| us-gaap |
Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
|
2158000 | USD | |
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
3932 | USD | |
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
8177 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
682712 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
376419 | USD | |
| us-gaap |
Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
|
2500000 | USD | |
| us-gaap |
Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
|
6425000 | USD | |
| CY2018Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
7385098 | USD |
| CY2019Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
10121935 | USD |
| us-gaap |
Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
|
0 | USD | |
| us-gaap |
Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
|
240000 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
200000 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
205000 | USD | |
| us-gaap |
Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
|
27500 | USD | |
| us-gaap |
Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
|
0 | USD | |
| us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
8000000 | USD | |
| us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
39600000 | USD | |
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
2347329 | USD | |
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
898102 | USD | |
| CY2018Q2 | us-gaap |
Profit Loss
ProfitLoss
|
7865593 | USD |
| us-gaap |
Profit Loss
ProfitLoss
|
23583248 | USD | |
| CY2019Q2 | us-gaap |
Profit Loss
ProfitLoss
|
10663931 | USD |
| us-gaap |
Profit Loss
ProfitLoss
|
8213802 | USD | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
12721082 | USD |
| CY2019Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
12101373 | USD |
| CY2018Q2 | us-gaap |
Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
|
12925000 | USD |
| us-gaap |
Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
|
31725000 | USD | |
| CY2019Q2 | us-gaap |
Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
|
15985000 | USD |
| us-gaap |
Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
|
26835000 | USD | |
| us-gaap |
Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
|
48999 | USD | |
| us-gaap |
Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
|
50490 | USD | |
| us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
257374 | USD | |
| us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
8040257 | USD | |
| CY2018Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
0 | USD |
| CY2019Q2 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
3537470 | USD |
| CY2018Q2 | us-gaap |
Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
|
8040870 | USD |
| CY2019Q2 | us-gaap |
Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
|
0 | USD |
| CY2018Q2 | us-gaap |
Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
|
745352 | USD |
| CY2019Q2 | us-gaap |
Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
|
4277682 | USD |
| CY2018Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
745470 | USD |
| CY2019Q2 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
740212 | USD |
| CY2018Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
17788203 | USD |
| CY2019Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
21473083 | USD |
| CY2019Q2 | us-gaap |
Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
|
0 | USD |
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
240500 | shares | |
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
111000 | shares | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
631562 | USD |
| CY2018Q2 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
0 | USD |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
142752 | USD |
| CY2019Q2 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
127999 | USD |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
180545832 | USD |
| CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
185399565 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
164183426 | USD |
| CY2018Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
122666531 | USD |
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
246589777 | USD | |
| CY2019Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
130049566 | USD |
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
225806737 | USD | |
| CY2019Q2 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
0 | USD |
| us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
0 | USD | |
| CY2019Q2 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
6441363 | USD |
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
15417482 | USD | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.0027 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0251 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
45000 | shares | |
| CY2019Q2 | us-gaap |
Share Price
SharePrice
|
18.11 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P3Y | ||
| CY2018Q4 | us-gaap |
Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
|
40257 | USD |
| CY2018Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
170488143 | USD |
| CY2018Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
174815156 | USD |
| CY2018Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
181544152 | USD |
| CY2019Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
182376770 | USD |
| CY2019Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
186089500 | USD |
| CY2019Q2 | us-gaap |
Sublease Income
SubleaseIncome
|
105900 | USD |
| us-gaap |
Sublease Income
SubleaseIncome
|
206080 | USD | |
| CY2018Q4 | us-gaap |
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
|
225117029 | USD |
| CY2019Q2 | us-gaap |
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
|
219582512 | USD |
| CY2018Q4 | us-gaap |
Treasury Stock Common Shares
TreasuryStockCommonShares
|
1850603 | shares |
| CY2019Q2 | us-gaap |
Treasury Stock Common Shares
TreasuryStockCommonShares
|
1944054 | shares |
| CY2019Q1 | us-gaap |
Treasury Stock Value Acquired Par Value Method
TreasuryStockValueAcquiredParValueMethod
|
0 | USD |
| us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
-16060 | USD | |
| us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
14549 | USD | |
| us-gaap |
Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
|
0.5 | ||
| CY2018Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
37850679 | shares |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
37935773 | shares | |
| CY2019Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
37962555 | shares |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
37896837 | shares | |
| CY2018Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
32674459 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
32548662 | shares | |
| CY2019Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
34540059 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
34518461 | shares | |
| CY2018Q4 | us-gaap |
Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
|
4996906 | USD |
| CY2019Q2 | us-gaap |
Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
|
3036271 | USD |
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risks</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.</font></div></div> | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Apollo Medical Holdings, Inc. (“ApolloMed”), entered into an Agreement and Plan of Merger dated as of December 21, 2016 (as amended on March 30, 2017 and October 17, 2017) (the “Merger Agreement”) among ApolloMed, Apollo Acquisition Corp., a California corporation and wholly-owned subsidiary of ApolloMed, Network Medical Management, Inc. (“NMM”), and Kenneth Sim, M.D. in his capacity as the representative of the shareholders of NMM, pursuant to which ApolloMed effected a merger with NMM (the “Merger”). The Merger closed and became effective on December 8, 2017 (the “Closing”). As a result of the Merger, NMM is now a wholly-owned subsidiary of ApolloMed and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed. For accounting purposes, the Merger is treated as a “reverse acquisition,” and NMM is considered the accounting acquirer and ApolloMed is the accounting acquiree. Accordingly, as of the Closing, NMM’s historical results of operations replaced ApolloMed’s historical results of operations for all periods prior to the Merger, and the results of operations of both companies are included in the accompanying condensed consolidated financial statements for all periods following the Merger.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The combined company, following the Merger, together with its affiliated physician groups and consolidated entities (collectively, the “Company”), is a physician-centric integrated population health management company providing coordinated, outcomes-based medical care in a cost-effective manner and serving patients in California, the majority of whom are covered by private or public insurance provided through Medicare, Medicaid and health maintenance organizations (“HMOs”). A small portion of the Company’s revenue is generated from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company’s physician network consists of primary care physicians, specialist physicians and hospitalists. The Company operates primarily through the following subsidiaries of ApolloMed: NMM, Apollo Medical Management, Inc. (“AMM”), APA ACO, Inc. ("APAACO") and Apollo Care Connect, Inc. (“Apollo Care Connect”), and their consolidated entities.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NMM was formed in 1994 as a management service organization (“MSO”) for the purposes of providing management services to medical companies and independent practice associations (“IPAs”). The management services include primarily billing, collection, accounting, administrative, quality assurance, marketing, compliance and education.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allied Physicians of California IPA, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (“APC”) was incorporated on August 17, 1992 for the purpose of arranging health care services as an IPA. APC has contracts with various HMOs and other licensed health care service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (“PMPM”) that is to be paid to APC. In return, APC arranges for the delivery of health care services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering health care services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 1, 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of </font><font style="font-family:inherit;font-size:10pt;">30 years</font><font style="font-family:inherit;font-size:10pt;">. In accordance with relevant accounting guidance, APC is determined to be a variable interest entity (“VIE”) of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC’s economic performance through its majority representation on the APC Joint Planning Board; therefore APC is consolidated by NMM. As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, APC had an ownership interest of </font><font style="font-family:inherit;font-size:10pt;">4.88%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">4.82%</font><font style="font-family:inherit;font-size:10pt;"> in ApolloMed, respectively.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concourse Diagnostic Surgery Center, LLC (“CDSC”) was formed on March 25, 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California. Its facility is Medicare Certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. During 2011, APC invested </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> for a </font><font style="font-family:inherit;font-size:10pt;">41.59%</font><font style="font-family:inherit;font-size:10pt;"> ownership interest in CDSC. APC’s ownership percentage in CDSC’s capital stock increased to </font><font style="font-family:inherit;font-size:10pt;">43.43%</font><font style="font-family:inherit;font-size:10pt;"> on July 31, 2016. CDSC is consolidated as a VIE by APC as it was determined that APC has a controlling financial interest in CDSC and is the primary beneficiary of CDSC.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APC-LSMA Designated Shareholder Medical Corporation ("APC-LSMA") was formed on October 15, 2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Chief Executive Officer of ApolloMed, is a nominee shareholder of APC. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA’s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (“LMA”), Pacific Medical Imaging and Oncology Center, Inc. (“PMIOC”), Diagnostic Medical Group (“DMG”) and AHMC International Cancer Center, a Medical Corporation (“ICC”). APC-LSMA also holds a </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> ownership interest in Maverick Medical Group, Inc. (“MMG”) and Alpha Care Medical Group, Inc. (“Alpha Care”).</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alpha Care, an IPA which has been operating in California since 1993 is a risk bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to over </font><font style="font-family:inherit;font-size:10pt;">180,000</font><font style="font-family:inherit;font-size:10pt;"> enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ICC was formed on September 2, 2010 in the state of California. ICC is a professional medical corporation that has entered into agreements with HMOs, IPAs, medical groups and other purchasers of medical services for the arrangement of services to subscribers or enrollees. On November 15, 2016, APC-LSMA, a holding company of APC, agreed to purchase and acquire from ICC </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;"> of the aggregate issued and outstanding shares of capital stock of ICC for </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> in cash. Certain requirements to complete the investment transaction were completed in August 2017 and effective on October 31, 2017, ICC was consolidated by APC as a VIE as it was determined that APC is the primary beneficiary of ICC through its obligation to absorb losses and right to receive benefits that could potentially be significant to ICC.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Universal Care Acquisition Partners, LLC (“UCAP”), a </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> owned subsidiary of APC, was formed on June 4, 2014, for the purpose of holding an investment in Universal Care, Inc. (“UCI”).</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APAACO, jointly owned by NMM and AMM, began participating in the next generation accountable care organization model (“NGACO Model”) of the Centers for Medicare & Medicaid Services ("CMS") in January 2017. The NGACO Model is a new CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. In addition to APAACO, NMM and AMM operated three accountable care organizations (“ACOs”) that participated in the Medicare Shared Savings Program (“MSSP”), with the goal of improving the quality of patient care and outcomes through a more efficient and coordinated approach among providers. MSSP revenues are uncertain, and, if such amounts are payable by CMS, they will be paid on an annual basis significantly after the time earned, and are contingent on various factors, including achievement of the minimum savings rate for the relevant period. Such payments are earned and made on an “all or nothing” basis.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, which consist of ApolloMed Hospitalists, a Medical Corporation (“AMH”), a hospitalist company, Southern California Heart Centers, a Medical Corporation (“SCHC”), Bay Area Hospitalist Associates, Inc. (“BAHA”), a Medical Corporation, ApolloMed Care Clinic, a Professional Corporation (“ACC”) and AKM Medical Group, Inc. (“AKM”). AMH provides hospitalist, intensivist and physician advisor services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. BAHA, ACC and AKM are no longer active to any material extent.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Apollo Care Connect, a wholly-owned subsidiary of ApolloMed, provides a cloud and mobile-based population health management platform that includes digital care plans, a case management module, connectivity with multiple healthcare tracking devices and the ability to integrate with multiple electronic health records to capture clinical data.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AP-AMH Medical Corporation (“AP-AMH”) was formed on May 7, 2019 as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder, and the Chief Executive Officer and Chief Financial Officer of APC and Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH. ApolloMed makes all the decisions on behalf of AP-AMH and funds and receives all the distributions from its operations. ApolloMed has the obligation to absorb losses or rights to receive benefits from the operations of AP-AMH. Therefore, AP-AMH is controlled and consolidated by ApolloMed as the primary beneficiary of this VIE.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 10, 2019, ApolloMed entered into a series of agreements with two of its affiliates, AP-AMH and APC as follows;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company agreed to lend AP-AMH </font><font style="font-family:inherit;font-size:10pt;">$545.0 million</font><font style="font-family:inherit;font-size:10pt;"> pursuant to a </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year secured loan agreement. The loan will bear interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> per annum simple interest, will not be prepayable (except in certain limited circumstances), will require quarterly payments of interest only, and will be secured by a first priority security interest in all of AP-AMH's assets, including the shares of APC Series A Preferred Stock to be purchased by AP-AMH, to the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock purchased with respect to such payment date in an amount insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of </font><font style="font-family:inherit;font-size:10pt;">10.75%</font><font style="font-family:inherit;font-size:10pt;"> per annum simple interest.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AP-AMH has agreed to purchase </font><font style="font-family:inherit;font-size:10pt;">$545.0 million</font><font style="font-family:inherit;font-size:10pt;"> of Series A Preferred Stock to be issued by APC to AP-AMH. Under the terms of the Series A Preferred Stock, AP-AMH is entitled to receive preferential, cumulative dividends that accrue on a daily basis and that are equal to the sum of (A) APC's net income from healthcare services, plus (B) any dividends received by APC from certain of APC's affiliated entities, less (C) any retained amounts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APC has agreed to purchase </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's common stock. The Company has agreed to grant APC certain registration rights with respect to the Company's common stock that APC purchases, and APC agreed to restrict its voting powers with respect to its shares.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company agreed to license certain of its trademarks to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through its subsidiary, the Company has agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The closing of foregoing transactions is contingent upon receiving the approval of the Company’s stockholders. ApolloMed is holding a special meeting of its stockholders on August 27, 2019 in order to obtain the stockholder approvals necessary to complete the foregoing transactions. If consummated, these transactions will result in a fundamental change in the character of APC’s healthcare services net income and how it is ultimately reflected on ApolloMed’s consolidated statements of income. If consummated, the foregoing transactions will substantially affect the Company’s future results of operations and its liquidity and capital resources.</font></div></div> | ||
| us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no material effect on the Company’s reported revenue, net income, cash flows or total assets.</font></div></div> | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred, but not reported (“IBNR”) claims), determination of full-risk and shared-risk revenue and receivables (including constraints and completion factors including historical medical loss ratios (“MLR”)), income taxes, valuation of share-based compensation and right of use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</font></div></div> |
